AlgiPharma AS is a clinical stage pharmaceutical company founded in August 2006, based on research and development carried out by FMC BioPolymer AS and the Biopolymer Foundation at the Norwegian University of Science and Technology in Trondheim, Norway. AlgiPharma’s aim is to address unmet medical needs, fighting diseases effectively through its innovative alginate oligomer technologies, by developing products and therapies to market or license to suitable partners. AlgiPharma AS owns or licenses all relevant patents upon which the technology platform and products are developed. AlgiPharma is supported by national and international research programs and grants, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA. AlgiPharma is a privately owned company registered and domiciled in Norway.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Enterprise Ireland is an Irish state economic development agency focused on helping Irish-owned business deliver new export sales. The aim of Enterprise Ireland is to accelerate the development of Irish enterprises capable of achieving strong positions in global markets resulting in increased national and regional prosperity and purchasing power.

The Board of Trustees of the University of Illinois, part of University of Illinois, is a company headquartered in Urbana, IL, that trusts Except Educational Religious.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Grape King Bio Ltd. engages in the production and sale of pharmaceutical preparations, patent medicine, liquid tonics, drinks, and healthy food. It operates through the following segments: Multi-Level Marketing (MLM), Distributors, and Original Design Manufacturer/Original Equipment Manufacturer (ODM/OEM). The MLM segment is involved in the direct seller of Pro-partner Inc., including the company’s development and manufacturing products for Pro-partner Inc., The Distributors segment include GRAPE KING BIO’s self-owned brand products. The ODM/OEM segment refers to the ODM/OEM in Taiwan and Shanghai. The company was founded by Shui Chao Tseng on April 1, 1971 and is headquartered in Taoyuan, Taiwan.

The Research Authority serves as the administrative and financial framework for research activities, scientific experiments and technical analyses carried out by Technion faculty, and TRDF staff. The missions of the Research & Development Division are: - Location, collection, processing and distribution of information concerning local and international research funding - Assistance in locating appropriate funding sources for Technion researchers - R&D information management services and in-campus marketing - Guidance and administrative services for Technion researchers in submitting research proposals to granting agencies and business entities - Management of contractual engagements with granting agencies and business entities - Contractual and budgetary administration of research grants and other accounts

Pharmaceutical concern

Transgenomic, Inc. (Transgenomic) provides products for the purification and analysis of nucleic acids used in the life sciences industry for research focused on molecular genetics and diagnostics. The Company also provides genetic variation analytical services to the medical research, clinical and pharmaceutical markets. Its products and services are categorized as Instrument Related Business and Laboratory Services. It has sold its products to customers in over 50 countries. Customers include numerous academic and medical institutions in the United States and abroad. In addition, its customers also include number of pharmaceutical, biotech and commercial companies both in the United States and abroad. In December 2010, the Company acquired Clinical Data, Inc.'s diagnostic business. ransgenomic, Inc. (www.transgenomic.com) is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The Company is the global leader in cardiac genetic testing with a family of innovative products, including its flagship C-GAAP test, designed to detect gene mutations which indicate cardiac disorders, or which can lead to serious adverse events. Transgenomic has three complementary business divisions: Transgenomic Clinical Laboratories, which specializes in molecular diagnostics for cardiology, oncology, neurology, and mitochondrial disorders; Transgenomic Pharmacogenomic Services, a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development; and Transgenomic Diagnostic Tools, which produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The Company actively develops and acquires new technology and other intellectual property that strengthens its leadership in personalized medicine.

NormOxys, Inc. operates as a biopharmaceutical company. It provides proprietary products that regulate the binding affinity between oxygen and hemoglobin. NormOxys, Inc. was formerly known as Oxyplus, Inc. and changed its name to NormOxys, Inc. in October 2008. The company was founded in 2003.

Phytera, Inc. develops plant-based and marine-based pharmaceuticals. The company is headquartered in Shrewsbury, MA.

Sichuan Jiuzhang Biotechnology Co., Ltd., established on 1999-04-27, Business scope includes drug research and development;chemical reagent(Free of Hazardous Chemicals)Research,Sales;Polymer Materials,biomaterials(Except for those prohibited by national laws and regulations and with special provisions)Research,Production,Sales;Sales:Chemical Products(Free of Hazardous Chemicals);Import and export,Technology Import and Export(National law,Except where prohibited by administrative regulations;law,Projects restricted by administrative regulations can only be operated after obtaining a license;The industrial industry involved in production establishes another branch or chooses another business site for operation);Sales of Jiuzhang Lutai Chewable Tablets(Operate within the validity period with the license).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

POSCO Holdings Inc. engages in the production of steel products. It operates through the following divisions: Steel, Engineering & Construction and Trading. The Steel division produces cold rolled, hot rolled and stainless steel products, plates, wire rods and silicon steel sheets. The Engineering & Construction division engages in the planning, designing and construction of industrial plants, civil engineering projects, commercial and residential buildings. The Trading division exports and imports steel products and raw materials. The company was founded by Tae-Joon Park on April 1, 1968 and is headquartered in Seoul, South Korea.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.